LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation

KRAS G12D mutation is one of the most prevalent subtypes in RAS mutant cancers. However, no results of KRAS G12D inhibitors from any clinical trials have been reported yet. HRS-4642 is a highly selective KRAS G12D inhibitor. Here, we report preliminary results of the dose escalation part of a first-in-human phase 1 study of HRS-4642 in patients (pts) with advanced KRAS G12D mutant solid tumors.